Arcutis Biotherapeutics, Inc. (ARQT): Total Liabilities
$243.49M
As of 2025-12-31
$267.96M
As of 2026-06-30
+0.5%
3-year compound annual growth
+54.5%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $243.49M | +27.3% | 2026-02-25, Balance as of period end |
| 2024-12-31 | $191.35M | -24.3% | 2026-02-25, Balance as of period end |
| 2023-12-31 | $252.70M | +5.4% | 2025-02-25, Balance as of period end |
| 2022-12-31 | $239.69M | +117.0% | 2024-02-27, Balance as of period end |
| 2021-12-31 | $110.47M | +299.6% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $27.65M | +398.2% | 2022-02-22, Balance as of period end |
| 2019-12-31 | $5.55M | n/a | 2021-02-16, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $243.49M | +27.3% |
| Sinovac Biotech Ltd (SVA) | 2025-12-31 | $2.15B | +5.0% |
| MannKind Corp (MNKD) | 2025-12-31 | $843.20M | +78.4% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $334.65M | +27.5% |
| CorMedix Inc. (CRMD) | 2025-12-31 | $420.83M | n/m |
| Zai Lab Ltd (ZLAB) | 2025-12-31 | $456.88M | +32.5% |
| Evolus, Inc. (EOLS) | 2025-12-31 | $248.97M | +9.7% |
| Xeris Biopharma Holdings, Inc. (XERS) | 2025-12-31 | $369.84M | +4.9% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $99.59M | +24.7% |
Compare ARQT, SVA, MNKD, ARDX side by side · Screen every company in Pharmaceutical Preparations ↗